2017-10-17 13:06:38 UTC

How Will Translational Advances in Pediatric IBD Affect Practices?

Oct. 17, 2017

Dr. Rosen will discuss how new findings can make a difference for pediatric IBD patients at the Crohn’s & Colitis Congress.

In the past year there have been tremendous translational advances in our understanding of the biology of pediatric inflammatory bowel disease (IBD) that will have important implications for how to assess IBD phenotype, predict treatment response and stratify therapy for  patients. 

Hear Michael Rosen, MD, MSCI, Cincinnati Children's Hospital Medical Center, as he critically assesses these studies and discusses how these findings can be applied to clinical practice to make a difference for pediatric patients. Register for AGA and the Crohn's & Colitis Foundation's Crohn's & Colitis Congress™, Jan. 18-20, 2018, in Las Vegas and add-on the Pre-Congress Workshop: Cutting-Edge Pediatric IBD to attend Dr. Rosen's session Translational Advances in Pediatric IBD – How Will It Affect My Practice? 

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.